Trial Search Results

Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:



  • Drug: maribavir
  • Other: placebo


Phase 3


Inclusion Criteria:

   - Allogeneic stem cell transplant recipient

   - Recipient or donor CMV seropositive

   - Have transplant engraftment

   - Able to swallow tablets

Exclusion Criteria:

   - CMV organ disease

   - HIV infection

   - Use of other anti-CMV therapy post-transplant

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Janice Brown
Not Recruiting